Estefania Linares Espinos

Estefania Linares Espinos

Auto-generated profile, based on publicly available information

Estefania Linares Espinos

Madrid, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in European Urology
Verified
Journal Article
Closed access
JWJ. Alfred Witjes
J. Alfred Witjes
TLThierry Lebret
Thierry Lebret
ECEva M. Compérat
Eva M. Compérat
NCNigel C. Cowan
Nigel C. Cowan
MSMaria De Santis
Maria De Santis
MRMaria J Ribal
Maria J Ribal

29 March 2014 in Current Urology Reports
Verified
Journal Article
Closed access
PDF file
Juan Ignacio Martínez-SalamancaJuan Ignacio Martínez-Salamanca
Juan Ignacio Martínez-Salamanca
ELEstefania Linares
Estefania Linares
JGJavier González
Javier González
RBRoberto Bertini
Roberto Bertini
JCJoaquín A. Carballido
Joaquín A. Carballido
JLJohn A. Libertino
John A. Libertino

21 December 2013 in Current Urology Reports
Verified
Journal Article
Closed access
PDF file
JGJavier Gonzalez
Javier Gonzalez
MEM. Esteban
M. Esteban
GAG. Andrés
G. Andrés
ELE. Linares
E. Linares
Juan Ignacio Martínez-SalamancaJuan Ignacio Martínez-Salamanca
Juan Ignacio Martínez-Salamanca

1 August 2015 in Journal of Urology
Verified
Journal Article
Closed access
HNHao G Nguyen
Hao G Nguyen
DTDerya Tilki
Derya Tilki
MDMarc A. Dall’era
Marc A. Dall’era
BDBlythe Durbin-Johnson
Blythe Durbin-Johnson
JCJoaquín A. Carballido
Joaquín A. Carballido
CEChristopher P. Evans
Christopher P. Evans
Purpose: The impact of cardiopulmonary bypass in level III-IV tumor thrombectomy on surgical and oncologic outcomes is unknown. We determine the impact of cardiopulmonary bypass on overall and cancer specific survival, as well as surgical complication rates and immediate outcomes in patients undergoing nephrectomy and level III-IV tumor thrombectomy with or without cardiopulmonary bypass. Materials and Methods: We retrospectively analyzed 362 patients with renal cell cancer and with level III or IV tumor thrombus from 1992 to 2012 at 22 U.S. and European centers. Cox proportional hazards models were used to compare overall and cancer specific survival between patients with and without cardiopulmonary bypass. Perioperative mortality and complication rates were assessed using logistic regression analyses. Results: Median overall survival was 24.6 months in noncardiopulmonary bypass cases and 26.6 months in cardiopulmonary bypass cases. Overall survival and cancer specific survival did not differ significantly in both groups on univariate analysis or when adjusting for known risk factors. On multivariate analysis no significant differences were seen in hospital length of stay, Clavien 1-4 complication rate, intraoperative or 30-day mortality and cancer specific survival. Limitations include the retrospective nature of the study. Conclusions: In our multi-institutional analysis the use of cardiopulmonary bypass did not significantly impact cancer specific survival or overall survival in patients undergoing nephrectomy and level III or IV tumor thrombectomy. Neither approach was independently associated with increased mortality on multivariate analysis. Greater surgical complications were not independently associated with the use of cardiopulmonary bypass.

1 February 2015 in Journal of Urology
Verified
Journal Article
Closed access
DTDerya Tilki
Derya Tilki
BHBrian Hu
Brian Hu
HNHao G Nguyen
Hao G Nguyen
MDMarc A. Dall’eRa
Marc A. Dall’eRa
RBRoberto Bertini
Roberto Bertini
CEChristopher P. Evans
Christopher P. Evans
Metastatic renal cell carcinoma can be clinically diverse in terms of the pattern of metastatic disease and response to treatment. We studied the impact of metastasis and location on cancer specific survival. The records of 2,017 patients with renal cell cancer and tumor thrombus who underwent radical nephrectomy and tumor thrombectomy from 1971 to 2012 at 22 centers in the United States and Europe were analyzed. Number and location of synchronous metastases were compared with respect to patient cancer specific survival. Multivariable Cox regression models were used to quantify the impact of covariates. Lymph node metastasis (155) or distant metastasis (725) was present in 880 (44%) patients. Of the patients with distant disease 385 (53%) had an isolated metastasis. The 5-year cancer specific survival was 51.3% (95% CI 48.6-53.9) for the entire group. On univariable analysis patients with isolated lymph node metastasis had a significantly worse cancer specific survival than those with a solitary distant metastasis. The location of distant metastasis did not have any significant effect on cancer specific survival. On multivariable analysis the presence of lymph node metastasis, isolated distant metastasis and multiple distant metastases were independently associated with cancer specific survival. Moreover higher tumor thrombus level, papillary histology and the use of postoperative systemic therapy were independently associated with worse cancer specific survival. In our multi-institutional series of patients with renal cell cancer who underwent radical nephrectomy and tumor thrombectomy, almost half of the patients had synchronous lymph node or distant organ metastasis. Survival was superior in patients with solitary distant metastasis compared to isolated lymph node disease.

26 August 2016 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
RMRene Mager
Rene Mager
SDSiamak Daneshmand
Siamak Daneshmand
CEChristopher P. Evans
Christopher P. Evans
JPJoan Palou
Joan Palou
JMJuan I. Martínez‐Salamanca
Juan I. Martínez‐Salamanca
RZRichard Zigeuner
Richard Zigeuner